EN
中文
IDN
Besides Lu-177 PSMA, at Beacon Hospital we treat neuroendocrine tumours with Lu-177 as well. The targeted radionuclide therapy Lutetium-177 Dotatate is used to treat neuroendocrine tumours (NETs). These tumours are caused by the neuroendocrine cells that are found all over the body and overseas producing and secreting different hormones. NETS can develop in a variety of organs, including the lungs, pancreas. And digestive system. Even while these tumours typically grow slowly, on occasion they can be aggressive and spread to other body sites which makes therapy more difficult.
What is Lutetium 177 (Lu-177) Dotatate Therapy?
A large dose of beta radiation is delivered directly to the cancer location using Lu-177 DOTATATE, which is preferentially absorbed by NET cells, sparing healthy tissues in the process. By using a focused method, the possibility of collateral harm to nearby healthy cells are minimised, and the adverse effects of conventional radiation therapy are reduced as well.
Lu-177 DOTATATE offers patients with advanced disease a focused, efficient and well-tolerated therapeutic alternative, marking a significant milestone in the management of neuroendocrine tumours. Its accomplishments demonstrate the promise of targeted radionuclide therapy in the larger context of cancer treatment and pave the way for advancement of more advanced therapies. Targeted radionuclide therapies such as Lu-177 PSMA and Lu-177 DOTATATE are promising to be a viable therapeutic option for metastatic prostate cancer and neuroendocrine tumours. Beacon Hospital is delighted to be the first in ASEAN to have this procedure done here.